Citizens Jmp Has Lowered Expectations for Avalo Therapeutics (NASDAQ:AVTX) Stock Price

Avalo Therapeutics (NASDAQ:AVTX) had its target price reduced by equities researchers at Citizens Jmp from $62.00 to $55.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s price objective points to a potential upside of 182.85% from the company’s current price.

AVTX has been the subject of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Wednesday, April 8th. BTIG Research increased their price objective on Avalo Therapeutics from $40.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Wolfe Research began coverage on shares of Avalo Therapeutics in a research note on Thursday, April 9th. They issued an “outperform” rating and a $48.00 target price for the company. Wedbush lowered their target price on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $60.00 price target (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Avalo Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $48.13.

Avalo Therapeutics Price Performance

NASDAQ:AVTX traded down $0.41 on Thursday, hitting $19.45. 195,228 shares of the company’s stock were exchanged, compared to its average volume of 1,002,079. The firm has a 50-day moving average price of $15.84 and a 200-day moving average price of $16.44. Avalo Therapeutics has a 52 week low of $3.43 and a 52 week high of $24.27. The company has a market cap of $570.32 million, a P/E ratio of -3.42 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.00) by $0.02. On average, research analysts expect that Avalo Therapeutics will post -3.1 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Mittie Doyle sold 3,970 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $18.01, for a total value of $71,499.70. Following the sale, the insider owned 3,622 shares in the company, valued at approximately $65,232.22. This represents a 52.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of the firm’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total value of $1,514,020.71. Following the sale, the insider directly owned 3,634 shares of the company’s stock, valued at $73,297.78. This represents a 95.38% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 138,078 shares of company stock valued at $2,501,346 over the last three months. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BIT Capital GmbH acquired a new stake in Avalo Therapeutics during the third quarter worth approximately $25,000. PFS Partners LLC increased its stake in shares of Avalo Therapeutics by 100.0% during the fourth quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock worth $36,000 after purchasing an additional 1,000 shares during the period. Boothbay Fund Management LLC bought a new position in shares of Avalo Therapeutics during the second quarter worth approximately $56,000. Dimensional Fund Advisors LP acquired a new stake in Avalo Therapeutics during the 3rd quarter worth approximately $143,000. Finally, AlphaCentric Advisors LLC acquired a new stake in Avalo Therapeutics during the 1st quarter worth approximately $174,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.